Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials

Journal of the Neurological Sciences

Volumn 152, Issue SUPPL. 1, 1997, Pages

  Cedarbaum, Jesse M ^a   Stambler, Nancy ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Amyotrophic lateral sclerosis; Clincal trials; Natural history; Rating scales; Validation

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FEEDING; GROOMING; HUMAN; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MOBILIZATION; MULTICENTER STUDY; MUSCLE STRENGTH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SELF CARE;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; HUMANS; LONGITUDINAL STUDIES; MULTICENTER STUDIES; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 0030678474     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00237-2     Document Type: Conference Paper

References (19)

1. ALS CNTF Treatment Study (ACTS) Group, A double-blind, placebo-controlled clinical trial of subcutaneous recombinant human Ciliary Neurotrophic Factor rHCNTF) in Amyotrophic Lateral Sclerosis (ALS). Neurology. 46:1996;1244-1249.
2. ALS CNTF Treatment Study Phase I-II Group (Brooks, B.R., Sanjak, M., Ringel, S., England, J., Brinkmann, J., Pestronk, A., Florence, J., Mitsumoto, H., Szirony, K., Wittes, J., Charatan, M., Stambler, N., Cedarbaum, J.M.), The ALS functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch. Neurol. 53:1996;141-147.
3. Appel V., Stewart S.S., Smith G., Appel S.H. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann. Neurol. 22:1987;328-333.
4. Bradley, W.G., BDNF Trial Group, 1995. A Phase I/II study of recombinant human brain-derived neurotrophic factor in patients with amyotrophic lateral sclerosis. Ann. Neurol. 38, 971.
5. Brooks. B.R., 1994. The Norris ALS score: insight into the natural history of amyotrophic lateral sclerosis provided by Forbes Norris. In: Rose, F.C. (Ed.), ALS - from Charcot to the present and into the future. Smith-Gordon, London, pp. 21-29.
6. Brooks B.R. Prognostic indicators of survival in amyotrophic lateral sclerosis (in collaboration with the ALS CNTF Treatment Study Group). Neurology. 46(Suppl):1996;A208.
7. Brooks B.R., Sufit R.L., DePaul R., DeTan Y., Sanjak M., Robbins J. Design of Clinical therapeutic trials in amyotrophic lateral sclerosis. Adv. Neurol. 56:1991;521-545.
8. Brooks B.R., Shodis K.A., Lewis D.H., Rawling J.D., Sanjak M., Belden D.S., Hakim H., DeTan Y., Gaffney J.M. Natural history of amyotrophic lateral sclerosis: quantification of symptoms, signs, strength and function. Adv. Neurol. 68:1995;163-184.
9. Fahn, S., Elton R., 1987. Unified Parkinson's disease rating scale. In: Fahn, S., Marsden, C. (Eds.), Recent Developments in Parkinson's Disease. Macmillan, New York, NY, pp. 153-163.
10. Florence J., Brinkmann J., Szirony K., Sanjak M., Brooks B., Pestronk A., Mitsumoto H., Neville H., Ringel S., Fisher M., Charatan M., Morse J., Stambler N., Cedarbaum J. Implementation of evaluation procedures in a multi-center study of treatment in ALS: ensuring reliability. Muscle Nerve. 1(Suppl):1994;S166.
11. Haverkamp L.J., Appel V., Appel S.H. Natural history of amyotrophic lateral sclerosis in a database population. Brain. 118:1995;707-719.
12. Hillel A.D., Miller R.M., Yorkston K., McDonald E., Norris F.H., Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology. 8:1989;142-150.
13. Hillel, A.D., Miller, R.M., Yorkston, K., McDonald, E., Norris, F.H., Konikow, N., 1990. Amyotrophic lateral sclerosis severity scale. In: Rose, F.C. (Ed.), Amyotrophic Lateral Sclerosis. Demos, New York, pp. 93-98.
14. Karnofsky, D.A., Burchenal, J.H., 1947. The clinical evaluation of chemotherapeutic agents in cancer. In: Maclead, C.M. (Ed.), Evaluation of Chemotherapeutic Agents. Columbia University Press, Irvington-on-Hudson, NY.
15. Louwerse, E.S., Vianney de Jong JMB, Keuther, G., 1990. Critique of assessment methodology in amyotrophic lateral sclerosis. In: Rose, F.C. (Ed.), Amyotrophic Lateral Sclerosis. Demos, New York, pp. 151-180.
16. Munsat T.L., Andres P.L., Finnison L., Conlon T., Thibodeau L. The natural history of motorneuron loss in amyotrophic lateral sclerosis. Neurology. 38:1988;409-413.
17. Norris F.H., Calanchini P.R., Fallat R.J., Panchari S., Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 24:1984;721-728.
18. Schwab, R., England, A., 1969. Project technique for evaluating surgery in Parkinson's disease. In: Gillingham, J., Donaldson, I. (Eds.), Third Symposium on Parkinson's Disease. E&S Livingstone, Edinburgh, Scotland, pp. 152-157.
19. Thurstone L.L. A method of scaling psychological and educational tests. J. Educ. Psychol. 16:1925;433-451.